CytomX

  • About
    • Overview
    • Vision & Mission
    • Our Values
    • Executive Team
    • Board of Directors
    • Scientific Advisory Board
    • Contact Us
  • Probody Therapeutics
    • Our Probody Approach
    • How Probody Therapeutics Work
    • A Versatile Platform
    • Scientific Publications & Presentations
  • Pipeline
    • Advancing a Pipeline
    • Lead Candidates
    • Clinical Trials
    • Access for HCPs/Patients
  • Partners
    • Opportunities
    • Current Partners
  • Investors & News
    • Corporate Profile
    • Press Releases
    • Events & Presentations
    • Scientific Publications
    • Corporate Governance
    • Stock Information
    • Financial & Filings
    • Analyst Coverage
    • Investor Resources
  • Culture & Careers
    • Overview
    • Xtraordinary Culture
    • Current Openings
    • Total Rewards Program
    • Corporate Amenities
  • Home
    • Terms of use
    • Privacy policy
    • Disclaimer for Twitter
Menu

Transforming lives with safer, more effective therapies.

Archives

Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-target Effects with Reduced Off-tumor Toxicity for Use in Immuno-Oncology

Clin Cancer Res; Autio, KA., Boni, V., Humphrey, RW. and Naing, A., October 2019.

Learn More

Contact Us

151 Oyster Point Blvd, Suite 400

South San Francisco, CA

94080-1913

Offices: 650-515-3185

Fax: 650-351-0353

Share

Linkedin Twitter © 2021 CytomX Therapeutics, Inc. | PROBODY, CYTOMX, and our corporate logo are U.S. registered trademarks of CytomX Therapeutics, Inc. IHZ is a trademark of CytomX Therapeutics, Inc. All other brands and trademarks referenced herein are the property of their respective owners.
  • About
    • Overview
    • Vision & Mission
    • Our Values
    • Executive Team
    • Board of Directors
    • Scientific Advisory Board
    • Contact Us
  • Probody Therapeutics
    • Our Probody Approach
    • How Probody Therapeutics Work
    • A Versatile Platform
    • Scientific Publications & Presentations
  • Pipeline
    • Advancing a Pipeline
    • Lead Candidates
    • Clinical Trials
    • Access for HCPs/Patients
  • Partners
    • Opportunities
    • Current Partners
  • Investors & News
    • Corporate Profile
    • Press Releases
    • Events & Presentations
    • Scientific Publications
    • Corporate Governance
    • Stock Information
    • Financial & Filings
    • Analyst Coverage
    • Investor Resources
  • Culture & Careers
    • Overview
    • Xtraordinary Culture
    • Current Openings
    • Total Rewards Program
    • Corporate Amenities
  • Home
    • Terms of use
    • Privacy policy
    • Disclaimer for Twitter